Zacks Small Cap Brokers Increase Earnings Estimates for HURA

TuHURA Biosciences (NASDAQ:HURA) – Zacks Small Cap boosted their Q3 2025 earnings per share estimates for TuHURA Biosciences in a research report issued on Monday, April 14th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.14) for the quarter, up from their prior estimate of ($0.15). Zacks Small Cap also issued estimates for TuHURA Biosciences’ Q4 2025 earnings at ($0.14) EPS, Q1 2026 earnings at ($0.15) EPS and Q2 2026 earnings at ($0.15) EPS.

A number of other research analysts have also weighed in on HURA. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th. Finally, HC Wainwright lowered their price objective on TuHURA Biosciences from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, April 3rd.

TuHURA Biosciences Trading Up 0.2 %

Shares of HURA opened at $4.15 on Wednesday. The stock has a fifty day moving average price of $3.27. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $7.93.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Accent Capital Management LLC purchased a new stake in TuHURA Biosciences in the 4th quarter valued at about $29,000. TT Capital Management LLC bought a new position in shares of TuHURA Biosciences in the fourth quarter valued at approximately $41,000. Jefferies Financial Group Inc. purchased a new stake in shares of TuHURA Biosciences during the fourth quarter valued at approximately $54,000. Bank of America Corp DE bought a new stake in TuHURA Biosciences during the fourth quarter worth $59,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in TuHURA Biosciences in the fourth quarter worth $61,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.